Document ID: chunk:federal_register_of_legislation:F2017C00843:reg:9:p1
Version: federal_register_of_legislation:F2017C00843
Segment Type: reg
Provision Reference: reg 9 (pt 1/2)
Character Range: 6094–9057

9               Factors that must exist
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting malignant neoplasm of the endometrium or death from malignant neoplasm of the endometrium with the circumstances of a person's relevant service:
(1)          for females aged over 35 years only, being nulliparous at the time of the clinical onset of malignant neoplasm of the endometrium;
Note: nulliparous is defined in the Schedule 1 - Dictionary.
(2)          using oestrogen-only hormone replacement therapy for at least three months before the clinical onset of malignant neoplasm of the endometrium, and where the use of oestrogen-only hormone replacement therapy has ceased, the clinical onset of malignant neoplasm of the endometrium has occurred within 30 years of cessation;
Note: oestrogen-only hormone replacement therapy is defined in the Schedule 1 - Dictionary.
(3)          having cyclical combined hormone replacement therapy for a continuous period of at least two years before the clinical onset of malignant neoplasm of the endometrium, and where the use of cyclical combined hormone replacement therapy has ceased, the clinical onset of malignant neoplasm of the endometrium has occurred within ten years of cessation;
Note: cyclical combined hormone replacement therapy is defined in the Schedule 1 - Dictionary.
(4)          having polycystic ovary syndrome at the time of the clinical onset of malignant neoplasm of the endometrium;
Note: polycystic ovary syndrome is defined in the Schedule 1 - Dictionary.
(5)          for post-menopausal females only, undergoing treatment with tamoxifen for a period of at least three months before the clinical onset of malignant neoplasm of the endometrium, and where treatment has ceased, the clinical onset of malignant neoplasm of the endometrium has occurred within 20 years of that period;
(6)          using the sequential oral contraceptive pill Oracon within the 20 years before the clinical onset of malignant neoplasm of the endometrium;
Note: sequential oral contraceptive pill Oracon is defined in the Schedule 1 - Dictionary.
(7)          being overweight or obese for a period of at least five years within the 20 years before the clinical onset of malignant neoplasm of the endometrium;
Note: being overweight or obese is defined in the Schedule 1 - Dictionary.
(8)          an inability to undertake any physical activity greater than three METs for at least ten years within the 30 years before the clinical onset of malignant neoplasm of the endometrium;
Note: MET is defined in the Schedule 1 - Dictionary.
(9)          having an oestrogen-secreting ovarian tumour before the clinical onset of malignant neoplasm of the endometrium;
Note: oestrogen-secreting ovarian tumour is defined in the Schedule 1 - Dictionary.
(10)      having diabetes mellitus for at least five years before the clinical onset